mRNA-5671
mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna.[1] It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene.[2] It is currently being evaluated for the treatment of either non-small cell lung cancer, colorectal cancers with microsatellite instability, or pancreatic adenocarcinoma, all with confirmed KRAS driver mutations.[3]
| Vaccine description | |
|---|---|
| Target | Cancer driven by G12D, G12V, G13D or G12C mutation in the KRAS gene |
| Vaccine type | mRNA |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code | |
References
- "mRNA 5671". AdisInsight. Springer Nature Switzerland AG.
- "mRNA-derived KRAS-targeted vaccine V941". National Cancer Institute Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.
- Clinical trial number NCT03948763 for "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.